We present here an assessment of a ‘real-life’ value of automated machine learning algorithm (AI) for examination of immunohistochemistry for fibroblast growth factor receptor-2 (FGFR2) in breast cancer (BC). This evidence concerns the gene FGFR2 and breast carcinoma.